Barbara Klughammer
Barbara Klughammer, Rheinfelden DE
Patent application number | Description | Published |
---|---|---|
20110184004 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides biomarkers which are predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients. | 07-28-2011 |
20110184005 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients. | 07-28-2011 |
20110195982 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients | 08-11-2011 |
20110212979 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients. | 09-01-2011 |
20110230506 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides a biomarker (RAPGEF5) that is predictive for the response to treatment with an EGFR inhibitor in cancer patients. | 09-22-2011 |
20110245279 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients | 10-06-2011 |
20110312981 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides a biomarker SFRS7 which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients. | 12-22-2011 |
20120095029 | IPP COMPLEX AS MARKER FOR ERLOTINIB TREATMENT - The present invention provides biomarkers which are predictive for the clinical benefit of erlotinib hydrochloride treatment in cancer patients. | 04-19-2012 |
20130210843 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients. | 08-15-2013 |
20130217712 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients. | 08-22-2013 |
20130217713 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients. | 08-22-2013 |
20130331287 | Autoimmune Antibodies - The invention generally relates to biomarkers associated with NSCLC, and methods and compositions for the detection and diagnosis of non-small cell lung cancer in a human subject. | 12-12-2013 |
20140272953 | EGFR Mutation Blood Testing - Improved methods of assessing status of a solid tumor cancer in a subject involving detection of tumor-associated mutations in the subject's blood. | 09-18-2014 |
Barbara Klughammer, Rhein Felden DE
Patent application number | Description | Published |
---|---|---|
20110218212 | PREDICTIVE MARKERS FOR EGFR INHIBITORS TREATMENT - The present invention provides biomarkers that are predictive for the response to treatment with an EGFR inhibitor in cancer patients. The markers are the genes GBAS, APOH, SCYL3, PMS2CL, PRODH, SERF1A, URG4A and LRRC31. | 09-08-2011 |